<- Go Home
Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Market Cap
$19.5M
Volume
16.7K
Cash and Equivalents
$26.2M
EBITDA
-$14.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$7.7M
Profit Margin
590.41%
52 Week High
$8.85
52 Week Low
$2.15
Dividend
N/A
Price / Book Value
0.89
Price / Earnings
-1.32
Price / Tangible Book Value
0.89
Enterprise Value
-$5.5M
Enterprise Value / EBITDA
0.37
Operating Income
-$14.8M
Return on Equity
60.22%
Return on Assets
-35.06
Cash and Short Term Investments
$26.2M
Debt
N/A
Equity
$23.3M
Revenue
$1.3M
Unlevered FCF
-$9.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium